We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Synchrony (SYF) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Synchrony (SYF - Free Report) will report quarterly earnings of $2.48 per share in its upcoming release, pointing to a year-over-year decline of 13.3%. It is anticipated that revenues will amount to $4.84 billion, exhibiting an increase of 2.5% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Synchrony metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Net interest margin' should come in at 15.5%. Compared to the current estimate, the company reported 15.6% in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Efficiency Ratio' of 34.8%. The estimate compares to the year-ago value of 32.6%.
The average prediction of analysts places 'Total - Period-end loan receivables' at $103.46 billion. Compared to the present estimate, the company reported $100.18 billion in the same quarter last year.
Analysts predict that the 'Total - Purchase volume' will reach $49.21 billion. The estimate is in contrast to the year-ago figure of $46.01 billion.
The combined assessment of analysts suggests that 'Net charge-offs as a % of average loan receivables, including held for sale' will likely reach 5.0%. Compared to the current estimate, the company reported 5.2% in the same quarter of the previous year.
The consensus estimate for 'Average Balance - Total interest-earning assets' stands at $122.71 billion. The estimate is in contrast to the year-ago figure of $119.89 billion.
The consensus among analysts is that 'Total - Average loan receivables, including held for sale' will reach $102.73 billion. Compared to the current estimate, the company reported $99.89 billion in the same quarter of the previous year.
Analysts forecast 'Platform Analysis - Diversified & Value - Period-end loan receivables' to reach $21.05 billion. Compared to the current estimate, the company reported $19.50 billion in the same quarter of the previous year.
Analysts' assessment points toward 'Platform Analysis - Diversified & Value - Average loan receivables, including held for sale' reaching $20.86 billion. Compared to the present estimate, the company reported $19.44 billion in the same quarter last year.
Analysts expect 'Platform Analysis - Health & Wellness - Purchase volume' to come in at $4.14 billion. The estimate compares to the year-ago value of $3.98 billion.
Based on the collective assessment of analysts, 'Platform Analysis - Health & Wellness - Period-end loan receivables' should arrive at $15.76 billion. Compared to the present estimate, the company reported $15.45 billion in the same quarter last year.
It is projected by analysts that the 'Platform Analysis - Health & Wellness - Average loan receivables, including held for sale' will reach $15.57 billion. Compared to the current estimate, the company reported $15.35 billion in the same quarter of the previous year.
Synchrony shares have witnessed a change of -4.2% in the past month, in contrast to the Zacks S&P 500 composite's +1.4% move. With a Zacks Rank #3 (Hold), SYF is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Image: Bigstock
Countdown to Synchrony (SYF) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts forecast that Synchrony (SYF - Free Report) will report quarterly earnings of $2.48 per share in its upcoming release, pointing to a year-over-year decline of 13.3%. It is anticipated that revenues will amount to $4.84 billion, exhibiting an increase of 2.5% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Synchrony metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Net interest margin' should come in at 15.5%. Compared to the current estimate, the company reported 15.6% in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Efficiency Ratio' of 34.8%. The estimate compares to the year-ago value of 32.6%.
The average prediction of analysts places 'Total - Period-end loan receivables' at $103.46 billion. Compared to the present estimate, the company reported $100.18 billion in the same quarter last year.
Analysts predict that the 'Total - Purchase volume' will reach $49.21 billion. The estimate is in contrast to the year-ago figure of $46.01 billion.
The combined assessment of analysts suggests that 'Net charge-offs as a % of average loan receivables, including held for sale' will likely reach 5.0%. Compared to the current estimate, the company reported 5.2% in the same quarter of the previous year.
The consensus estimate for 'Average Balance - Total interest-earning assets' stands at $122.71 billion. The estimate is in contrast to the year-ago figure of $119.89 billion.
The consensus among analysts is that 'Total - Average loan receivables, including held for sale' will reach $102.73 billion. Compared to the current estimate, the company reported $99.89 billion in the same quarter of the previous year.
Analysts forecast 'Platform Analysis - Diversified & Value - Period-end loan receivables' to reach $21.05 billion. Compared to the current estimate, the company reported $19.50 billion in the same quarter of the previous year.
Analysts' assessment points toward 'Platform Analysis - Diversified & Value - Average loan receivables, including held for sale' reaching $20.86 billion. Compared to the present estimate, the company reported $19.44 billion in the same quarter last year.
Analysts expect 'Platform Analysis - Health & Wellness - Purchase volume' to come in at $4.14 billion. The estimate compares to the year-ago value of $3.98 billion.
Based on the collective assessment of analysts, 'Platform Analysis - Health & Wellness - Period-end loan receivables' should arrive at $15.76 billion. Compared to the present estimate, the company reported $15.45 billion in the same quarter last year.
It is projected by analysts that the 'Platform Analysis - Health & Wellness - Average loan receivables, including held for sale' will reach $15.57 billion. Compared to the current estimate, the company reported $15.35 billion in the same quarter of the previous year.
View all Key Company Metrics for Synchrony here>>>Synchrony shares have witnessed a change of -4.2% in the past month, in contrast to the Zacks S&P 500 composite's +1.4% move. With a Zacks Rank #3 (Hold), SYF is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .